Tat protein from human immunodeficiency virus can deliver biologically active proteins in vivo and is of considerable interest for protein therapeutics. The mechanism responsible for Tat-fusion protein internalization is still poorly understood and controversial. The punctuate distribution, timing, and temperature sensitivity observed in our experiments with Tat-fusion proteins are consistent with endocytosis. After a few hours, Tat-fusion proteins accumulated around the nucleus without any significant visible nuclear targeting. Using a Cre/Lox based functional assay, lysosomotropic agents known to disrupt endosome integrity, increased by up to 23-fold the nuclear delivery of functional Tat-Cre recombinase without increasing cell uptake in a similar fashion. This shows that endosome disruption can significantly increase Tat-fusion protein access to the cytosol and nucleus. In addition, we found that internalized Tat-fusion proteins persisted several hours and that inhibitors of lysosome acidification did not increase functional nuclear delivery of Tat-Cre. This suggests that Tat-fusion proteins enter via the endosomal pathway, circumvent lysosomal degradation, and are then sequestered in the periphery of the nucleus. Most importantly, our work indicates that an inadequate intracellular trafficking is the main factor limiting the efficiency of protein cargo delivery using Tat.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2004.04.180DOI Listing

Publication Analysis

Top Keywords

tat-fusion proteins
20
nuclear delivery
12
endosome disruption
8
functional nuclear
8
tat-fusion protein
8
tat-fusion
7
proteins
6
protein
5
disruption enhances
4
functional
4

Similar Publications

Article Synopsis
  • Acute myeloid leukemia (AML) is a complex and aggressive form of blood cancer, characterized by various subgroups that complicate treatment development.
  • Researchers have engineered two multifunctional fusion proteins to deliver targeted anti-cancer therapies specifically to leukemia cells by combining several components that enhance cell uptake and delivery.
  • Initial testing shows promise for these proteins, demonstrating effective binding, cellular absorption, and the ability to enter the nucleus without harming normal cells, suggesting potential for improved cancer treatment methods.
View Article and Find Full Text PDF

The intrinsically disordered protein MeCP2 is a global transcriptional regulator encoded by the MECP2 gene. Although the structured domains of MeCP2 have been the subject of multiple studies, its unstructured regions have not been that extensively characterized. In this work, we show that MeCP2 possesses properties akin to those of supercharged proteins.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated the use of engineered outer membrane vesicles (OMVs) from ClearColi™ as both an adjuvant and a carrier for a novel vaccine targeting HIV-1 antigens Nef and Nef-Tat.
  • Researchers isolated recombinant OMVs (rOMVs) containing specific fusion proteins and confirmed their presence through western blotting.
  • Results showed that rOMVs induced stronger immune responses, including higher levels of IgG2a and IFN-γ, compared to traditional adjuvants, indicating their potential as effective vaccine carriers against HIV-1.
View Article and Find Full Text PDF
Article Synopsis
  • Antigen presenting cells (APCs) can produce exosomes that enhance T cell responses and have potential therapeutic benefits for conditions like HIV-1 infection.
  • Researchers explored how vaccines made from dendritic cells (DCs) and engineered exosomes with HIV-1 proteins and heat shock protein (Hsp70) affected immune responses in mice.
  • The study found that the combination of exosomes carrying HIV-1 proteins and Hsp70 significantly boosted the levels of key immune markers (like antibodies and cytokines), suggesting this approach could be a promising and safe vaccine strategy against HIV-1.
View Article and Find Full Text PDF

Background: Heterologous combinations in vaccine design are an effective approach to promote T cell activity and antiviral effects. The goal of this study was to compare the homologous and heterologous regimens targeting the Nef-Tat fusion antigen to develop a human immunodeficiency virus-1 (HIV-1) therapeutic vaccine candidate.

Methods: At first, the DNA and protein constructs harboring HIV-1 Nef and the first exon of Tat as linked form (pcDNA- and Nef-Tat protein) were prepared in large scale and high purity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!